Method of reducing pulmonary exacerbations in respiratory disease patients
AssigneeCelltaxis, LLC
InventorsSanjeev Ahuja, Ralph Grosswald, Gregory S. Duncan, Eric B. Springman
Life of this patent
Estimating the term…
Abstract
Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
Claims24
A method of reducing pulmonary exacerbations in a cystic fibrosis patient, wherein the patient is undergoing concomitant treatment with a CFTR modulator and wherein the patient has an FEV1pp greater than or equal to about 68% at baseline, the method comprising orally administering to the patient acebilustat at a total daily dose of about 100 mg or less, and wherein the CFTR modulator is selected from the group consisting of ivacaftor, lumacaftor, tezacaftor, VX-445, VX-659, VX-440 and VX-152, or a combination of any of thereof.
A method of reducing pulmonary exacerbations in a cystic fibrosis patient, wherein the patient is undergoing concomitant treatment with a CFTR modulator, the method comprising measuring FEV1pp in the patient at baseline, and orally administering acebilustat at a total daily dose of about 100 mg or less to the patient if the patient has an FEV1pp greater than or equal to about 68% at baseline;
- wherein the CFTR modulator is selected from the group consisting of ivacaftor, lumacaftor, tezacaftor, VX-445, VX-659, VX-440 and VX-152, or a combination of any of thereof.
Dependencies are inferred from the claim text.